Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2015: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
Outline of Final Research Achievements |
Recently immunotherapy are promising cancer therapy. However, the biomarker evaluating immunological condition is not established. In the present study, We have identified IL-6 and 8 as a critical biomarker in oral cancer. We showed that the serum IL-6 level tended to negatively correlate with favorable outcome. And IL-6 has important roles in cancer progression via angiogenesis. IL-8 may be involved in poor clinical outcomes via generation of CD163-positive M2 macrophages. These findings obtained from this study lead to development of personalized immunochemotherapy for oral cancer patients.
|